The report on ‘Global Structural Heart Devices Market’ available with MarketStudyReport, states that global structural heart devices market accounted for USD 5.87 billion in 2021 and is poised to register a healthy CAGR of 9.15% during the forecast period, while amassing USD 10.83 billion by the end of 2028.

High prevalence of the target condition, improved neonatal screening programs, high desire for minimally intrusive treatments, increased knowledge of cardiac disorders, and improved healthcare access are the major factors driving global structural heart devices market expansion.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/5489990/

For those unaware, structural heart disease (SHD) refers to a broad group of percutaneous therapies for patients with both acquired and congenital heart disease (CHD). The treatment address both functional and anatomical problems of the cardiac chambers, heart valves, and proximal great arteries.

It is anticipated by researchers that the financial situation is likely to improve, thereby lowering the cost of procedures like TAVR (Transcatheter Aortic Valve Replacement).

Besides, institutions such as Centers for Medicare and Medicaid Services (CMS) is predicted to bear the medical bills as the target demographic ages Thus, by easing the financial burden of healthcare, more people are expected to seek treatment. This positively affects procedures that reduce the risk of stroke, such as the Left Atrial Appendage Closure (LAAC), thus supporting the industry development

However, the market will experience slower development due to rigorous compliance standards over the estimated period.

Worldwide structural heart devices business space is analyzed on the basis of type to give a clear depiction of the current situation to the interested parties. By type, the market is divided into surgical aortic valve replacement, mitral repair, transcatheter aortic valve replacement, and left atrial appendage closure.

In terms of regional analysis, this marketplace is studied across Asia Pacific, North America, Latin America, Europe, and the rest of the world. Among these, North America market is expected to register a significant growth rate over the study period,
owing to the high desire for least intrusive treatments.

Whereas Asia Pacific industry is estimated to generate sustainable gains during the forecast period, due to improved neonatal screening programs, increased knowledge of cardiac disorders, and better healthcare access.

The major companies defining the competitive landscape of global structural heart devices industry are CardioKinetix, LivaNova PLC, JenaValve Technology Inc., Comed B.V., Biomerics, Abbott Laboratories, Edwards Lifesciences Corporation, Medtronic PLC, and Boston Scientific Corporation.